What is conjunctival melanoma?
Conjunctival melanoma is a rare cancer of the conjunctiva, the thin, clear membrane that covers the white of the eye and lines the inside of the eyelids. It develops from melanocytes, the cells that make pigment. It is different from uveal melanoma, which grows inside the eye, and it behaves more like melanoma of the skin and mucous membranes.
The disease is uncommon, with roughly one new case per million people each year. Numbers appear to be rising, particularly in people over 65 (Butt et al., 2024). Most patients are fair-skinned adults in later life.
Conjunctival melanoma often appears as a brown or pinkish patch or lump on the surface of the eye. Many cases grow from a flat, freckle-like area of pigment called primary acquired melanosis (PAM). Others grow from an existing mole (naevus) or appear without any earlier lesion.
Although it starts on the surface, conjunctival melanoma can come back locally, spread to lymph nodes in front of the ear or in the neck, and less often spread to distant organs. Early diagnosis and careful surgery at a specialist eye cancer (ocular oncology) centre give the best results.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | Melanoma of the conjunctiva (surface lining of the eye) |
| How common | Very rare; about 1 per million people per year |
| Typical age | Usually over 50; most often in the 60s and 70s |
| Who is affected | Mostly white adults; men and women in similar numbers |
| Main precursor | Primary acquired melanosis (PAM) with atypia |
| Spread | Local recurrence, lymph nodes near the ear and in the neck, then distant organs |
| Main treatment | Careful surgical removal with additional treatment to the surface of the eye |
| Outlook | Most people survive; risk depends on location, thickness and origin |
2. Types of conjunctival melanoma
Doctors describe conjunctival melanoma by where it came from and where it sits.
By origin
In a large series of 382 patients, about three-quarters of melanomas arose from PAM, around 7% from a naevus, and roughly one in five de novo, meaning with no earlier lesion (Shields et al., 2011).
| Origin | Share of cases | Notes |
|---|---|---|
| From PAM | About 74% | Most common; often a wider, flat area of pigment |
| From a naevus | About 7% | Grows from a long-standing mole |
| De novo | About 19% | Linked to a higher risk of spread and death |
By location
| Location | Notes |
|---|---|
| Bulbar conjunctiva | Covers the white of the eye; the most common and most visible site |
| Limbus | The edge where the white meets the cornea |
| Fornix | The deep folds where the eyelid lining meets the eye; harder to see |
| Palpebral (tarsal) conjunctiva | Inner surface of the eyelid; harder to see |
| Caruncle | The small pink mound in the inner corner of the eye |
Melanomas in less visible places, such as the fornix, inner eyelid or caruncle, tend to be found later and carry a higher risk (Shields et al., 2011).
How it compares with other eye melanomas
| Feature | Conjunctival melanoma | Uveal melanoma |
|---|---|---|
| Where it grows | Surface of the eye | Inside the eye |
| Visible in a mirror | Often | Rarely |
| Main genes | BRAF, NRAS, NF1, similar to skin melanoma | GNAQ, GNA11, BAP1 |
| Spread | Lymph nodes first, then distant organs | Mainly to the liver, via the blood |
| Treatment | Surgery, cryotherapy, eye drops | Radiotherapy, surgery |
3. Causes and risk factors
The exact cause is not fully understood. Like skin melanoma, conjunctival melanoma often carries changes in genes such as BRAF, NRAS and NF1, and the pattern suggests that ultraviolet light plays a part in some cases (Grimes et al., 2020).
| Risk factor | Notes |
|---|---|
| Primary acquired melanosis with atypia | The main precursor; risk rises with the degree of atypia and the size of the patch |
| Conjunctival naevus | A mole of the eye surface; only rarely becomes cancer |
| Fair skin | Most patients are white |
| Older age | Risk rises sharply after 65 |
| Sunlight exposure | Probably contributes, especially on exposed parts of the eye |
| Immune suppression | May increase risk |
Most freckles and moles on the eye never become melanoma, but new or changing pigment should always be checked.
4. How does it look
On the surface of the eye
| Feature | Description |
|---|---|
| Colour | Brown, black, or sometimes pink or skin-coloured (amelanotic) |
| Shape | A raised nodule, often with a flatter pigmented area around it |
| Blood vessels | Large feeder vessels may run to the lump |
| Size | From a few millimetres to more than 1 cm |
| Movement | Usually moves slightly with the conjunctiva over the white of the eye |
| Bleeding | Some lumps bleed easily |
Compared with a harmless mole
| Feature | Benign naevus | Melanoma |
|---|---|---|
| Onset | Often present since childhood | New in adulthood |
| Change | Stable for years | Growing, thickening or spreading |
| Cysts inside | Common | Uncommon |
| Location | Usually on the white of the eye | May be in the fornix, eyelid or cornea |
| Feeder vessels | Uncommon | Common |
Under the microscope
Melanoma cells are atypical pigment cells that have grown through the surface layer of the conjunctiva into the tissue beneath. The pathologist measures the tumour thickness and looks for ulceration, which helps predict the risk of spread.
5. Symptoms
Common signs
- A new brown or pink spot or lump on the white of the eye or inside the eyelid
- A change in size, colour or thickness of an existing spot
- Redness or prominent blood vessels in one area
- A feeling that something is in the eye
Less common symptoms
| Symptom | What it may mean |
|---|---|
| Bleeding from the eye surface | Fragile tumour vessels |
| Irritation or discharge | Inflammation around the tumour |
| Lump in front of the ear or under the jaw | Possible lymph node spread |
| Blurred vision | Growth onto the cornea, which is uncommon |
When to seek medical advice
See an optician or eye doctor promptly if you notice any new pigmented spot on the eye, or a change in an existing one, particularly after the age of 40. Early melanomas are often painless, so do not wait for discomfort.
6. Diagnosis
| Test | Purpose |
|---|---|
| Slit-lamp examination | A magnified view of the eye surface |
| Eyelid eversion | Turning the lids to check the inner surfaces and fornices |
| Clinical photographs | Record the lesion so change can be measured |
| Anterior segment OCT or ultrasound | Shows depth and whether the tumour invades the eye |
| Biopsy | Ideally an excisional biopsy that removes the whole lesion |
| Lymph node examination and ultrasound | Checks nodes near the ear and in the neck |
| CT, MRI or PET-CT | For thicker tumours or suspected spread |
| Genetic testing of the tumour | Looks for BRAF or other changes relevant to drug treatment |
Small cuts into the tumour can spread cells, so specialists usually prefer to remove the whole lesion in one piece where possible.
Staging
Conjunctival melanoma is staged with the TNM system:
| Stage component | What it describes |
|---|---|
| T (tumour) | Location (bulbar or non-bulbar), number of quadrants involved, and invasion of the eyelid, eye or orbit |
| N (nodes) | Whether regional lymph nodes contain melanoma |
| M (metastasis) | Whether it has spread to distant organs |
Sentinel lymph node biopsy
For thicker or higher-risk tumours, some centres offer a sentinel lymph node biopsy, which samples the first node that drains the area. In one Slovenian series, about one in seven of these biopsies found melanoma in the node (Peric et al., 2021). Its exact role is still being studied.
7. Treatment
Treatment should be planned at a specialist ocular oncology centre.
Surgery
The main treatment is a “no-touch” excision: the surgeon removes the tumour with a margin of healthy tissue without handling the tumour itself, to avoid spreading cells.
| Step | Purpose |
|---|---|
| Excision with margins | Removes the tumour in one piece |
| Alcohol to the corneal surface | Loosens and removes surface cells near the cornea |
| Freezing (cryotherapy) to the edges | Destroys microscopic cells left at the margins |
| Covering the wound | With a graft of conjunctiva or amniotic membrane |
Additional local treatments
| Treatment | When it is used |
|---|---|
| Mitomycin C eye drops | For residual PAM or to lower recurrence risk |
| Interferon eye drops | An alternative topical treatment |
| Plaque brachytherapy | Radiation placed on the eye for deeper or residual disease |
| External beam or proton radiotherapy | For widespread or recurrent disease |
Advanced local disease
If the melanoma has grown into the eye socket or is too widespread to remove, an operation called orbital exenteration, which removes the eye and surrounding tissues, may be needed. This is now less common thanks to earlier diagnosis and other treatments.
Treatment for spread
| Situation | Options |
|---|---|
| Lymph node spread | Surgery to the neck or parotid nodes, sometimes radiotherapy |
| Distant spread | Immunotherapy such as PD-1 and CTLA-4 inhibitors |
| BRAF mutation present | BRAF and MEK inhibitor tablets |
| KIT mutation present | KIT inhibitors in selected cases |
Because conjunctival melanoma is genetically similar to skin melanoma, many of the newer skin melanoma drugs appear to work for it too (Grimes et al., 2020).
Side effects
| Treatment | Possible side effects |
|---|---|
| Surgery and cryotherapy | Redness, discomfort, scarring, dry eye |
| Mitomycin C | Stinging, redness, surface irritation |
| Radiotherapy | Dry eye, cataract, eyelash loss |
| Exenteration | Loss of the eye; an artificial eye or prosthesis is fitted |
| Immunotherapy | Tiredness, rash, inflammation of organs |
8. Outlook (prognosis)
Most people with conjunctival melanoma survive, but the tumour can recur locally and a minority develop spread.
In the 382-patient series, the risk of metastasis at 10 years was about a quarter for melanomas arising from PAM or a naevus, compared with nearly half for de novo tumours. Melanoma-related death at 10 years was about 9% for the first two groups and about 35% for de novo melanoma (Shields et al., 2011).
| Factor | Effect on outlook |
|---|---|
| De novo origin | Higher risk |
| Non-bulbar location (fornix, eyelid, caruncle) | Higher risk |
| Nodular, thick tumour | Higher risk |
| Invasion of the orbit | Higher risk |
| Ulceration | Higher risk |
| Local recurrence | Higher risk of later spread |
| Thin bulbar tumour fully removed | Best outlook |
9. Follow-up
| Follow-up | Purpose |
|---|---|
| Eye examination every 3-6 months at first | Checks for recurrence and new PAM |
| Clinical photographs | Compare changes over time |
| Lymph node checks | By examination and sometimes ultrasound |
| Scans for higher-risk tumours | Look for distant spread |
| Lifelong eye checks | New lesions can appear many years later |
10. Living with conjunctival melanoma
- Look at your eyes in a mirror regularly, lifting the lids, and report new spots
- Wear sunglasses that block ultraviolet light
- Use lubricating drops for dry or gritty eyes after treatment
- Attend every follow-up appointment
- Ask about support if you need an artificial eye or have changes to your appearance
- Seek help from eye cancer and melanoma charities
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is it the same as eye melanoma inside the eye? | No; uveal melanoma is a different disease |
| Will I lose my eye? | Most people keep their eye; removal is needed only for advanced disease |
| Will I lose my vision? | Usually not, unless the tumour or treatment affects the cornea |
| Is it inherited? | Not usually |
| Can it come back? | Yes, locally, which is why lifelong checks are needed |
| Can a freckle on my eye become cancer? | Rarely; any change should be checked |
| Do skin melanoma drugs work? | Often, because the gene changes are similar |
12. Questions to ask your care team
- Where did my melanoma start, and is it bulbar or non-bulbar?
- How thick was it, and were the margins clear?
- Do I need eye drops or radiotherapy after surgery?
- Should I have a sentinel lymph node biopsy?
- Does my tumour have a BRAF or other mutation?
- How often will I need eye and node checks?
Resources
- Butt, K. et al. (2024) ‘Conjunctival melanoma: a clinical review and update’, Cancers, 16(18), 3121.
- Grimes, J.M. et al. (2020) ‘Conjunctival melanoma: current treatments and future options’, American Journal of Clinical Dermatology, 21(3), pp. 371-381.
- Peric, B. et al. (2021) ‘Sentinel node biopsy for conjunctival melanoma; single centre experience and review of current literature’, Cancer Control, 28, 10732748211042116.
- Shields, C.L. et al. (2011) ‘Conjunctival melanoma: outcomes based on tumor origin in 382 consecutive cases’, Ophthalmology, 118(2), pp. 389-395.
Prepared by the editorial team, October 2026.